Literature DB >> 35661266

Commentary: Should we "keep rollin'" for PA/VSD/MAPCA?

Raymond J Strobel1, Andrew M Young1, Irving L Kron1.   

Abstract

Pulmonary atresia with ventricular septal defect and major aortopulmonary collateral arteries (PA/VSD/MAPCA) represents an anatomically diverse and technically demanding spectrum of congenital disease. Here, we review a manuscript by Onalan et al. in the Journal of Cardiac Surgery detailing a retrospective, single-center cohort study of patients undergoing unifocalization for PA/VSD/MAPCA via either a pulmonary artery patch augmentation or pericardial roll technique. While they report statistically equivalent outcomes using both techniques, longer follow-up and increased sample size are necessary to determine efficacy and safety.
© 2022 Wiley Periodicals LLC.

Entities:  

Keywords:  congenital heart disease

Mesh:

Year:  2022        PMID: 35661266      PMCID: PMC9383053          DOI: 10.1111/jocs.16651

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.778


  3 in total

Review 1.  Surgical management of pulmonary atresia with ventricular septal defect and major aortopulmonary collaterals: a protocol-based approach.

Authors:  Sunil P Malhotra; Frank L Hanley
Journal:  Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu       Date:  2009

2.  Unifocalization with pericardial roll technique in pulmonary atresia with ventricular septal defect and major aortopulmonary collateral arteries.

Authors:  Mehmet Akif Onalan; Murat Cicek; Mehmet Rum; Okan Yurdakok; Fatih Ozdemir; Oktay Korun; Husnu Firat Altin; Hasan Erdem; Emine H Yilmaz; Numan A Aydemir; Ahmet Sasmazel
Journal:  J Card Surg       Date:  2022-06-03       Impact factor: 1.778

3.  Staged repair of pulmonary atresia with ventricular septal defect and major aortopulmonary collateral arteries: experience with 104 patients.

Authors:  Anuja Gupta; Jonah Odim; Daniel Levi; Ruey-Kang Chang; Hillel Laks
Journal:  J Thorac Cardiovasc Surg       Date:  2003-12       Impact factor: 5.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.